ChemicalBook
Chinese Japanese Germany Korea

Eptifibatide

Pharmacological effects Eptifibatide
Eptifibatide
Eptifibatide structure
CAS No.
148031-34-9
Chemical Name:
Eptifibatide
Synonyms
INTEGRELIN;Eptifitide;Eptifibatide;EFTIFIBATIDE;Human Eptifibatide;EPTIFIBATIDE ACETATE;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;Mpr-Harg-Gly-Asp-Trp-Pro-Cys-NH2,( Disulfide Bridge:1-7);Map-Har-Gly-Asp-Trp-Pro-Cys-NH2(Disulfide bridge, Map1-Cys6);Mpr-Harg-Gly-Asp-Trp-Pro-Cys-NH2,( Disulfide Bridg on Mpr and Cys)
CBNumber:
CB7416565
Molecular Formula:
C35H49N11O9S2
Formula Weight:
831.96
MOL File:
148031-34-9.mol

Eptifibatide Properties

CAS DataBase Reference
148031-34-9(CAS DataBase Reference)
FDA UNII
NA8320J834

Eptifibatide Chemical Properties,Uses,Production

Pharmacological effects

Eptifibatide is a platelet glycoprotein Ⅱb/Ⅲa receptor reversible antagonist,adverse reactions are mild , it can be discontinued immediately while adverse reactions occur . It has Strong effect and high selectivity . It has no antigenicity,and it does not cause allergic reactions. It is used For acute coronary syndrome, coronary intervention before treatment and acute Q-wave myocardial infarction. It can relieve unstable angina symptoms and reduce the incidence of cardiovascular events. It can limit the non-Q-wave myocardial infarction,and reduce through wall myocardial infarction occurrance.
Eptifibatide is used to treat acute coronary syndrome, the starting amount is 180μg/kg, the intravenous maintenance dose is per minute 2μg/kg continuous intravenous infusion 72h, if implementing the primary percutaneous coronary intervention, continuous intravenous drip after surgery is 18~24h. For percutaneous coronary intervention, the starting amount is 180μg/kg intravenous injection, after 2μg/kg continuous intravenous infusion every minute, after 10 min, administrated again with 180μg/kg intravenously per minute , thereafter 2μg/kg continuous intravenous infusion for 18~24h.

Eptifibatide

Eptifibatide is a cyclic heptapeptide, by preventing fibrinogen, von Willebrand factor and other adhesive ligands binding to GPIIb/IIIa , it can reversibly inhibit platelet aggregation. When administrated intravenously, vitro inhibition of platelet aggregation of eptifibatide is in a dose-and concentration-dependent manner. Inhibition of platelet aggregation is reversible after Eptifibatide infusion is stopped , which is believed to be caused by dissociation of eptifibatide and platelet.
Platelet membrane glycoprotein (GP) Ⅱb/Ⅲa receptor antagonists: after platelet activation, platelet membrane GP Ⅱb/Ⅲa receptor changes its conformation to bind to the end of fibrinogen dimer to complete platelet aggregation. So, GP Ⅱb/Ⅲa receptor is believed to be the final common pathway of platelet aggregation. platelet GP Ⅱb/Ⅲa receptor antagonist Currently in clinical use, it has the following three types; ① abciximab (Abciximab reopro) is the Fab fragment of a monoclonal antibody of platelet GP Ⅱb/Ⅲa receptor. ②Eptifibatide, Integrilin is a cyclic heptapeptide. ③ tirofiban is a small molecule non-peptide compound.
Eptifibatide for injection is a small molecule with heptapeptide containing Lys-Gly-Asp amino acid sequence (KGD), which is like fibrinogen recognizing and binding site GPⅡb/Ⅲa receptors ,it can highly and specially bind to platelets GPⅡb/Ⅲa receptors, it is the GPⅡb/Ⅲa receptor specific competitive inhibitor ,with a low affinity, high dissociation rate, short plasma half-life , platelet aggregation restores baseline levels within 4-8 hours after stopping the infusion . American College of Cardiology (ACC) and the American Heart Association (AHA) guidelines recommend eptifibatide injection can be used for acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction) or supporting through percutaneous coronary intervention (PCI) drug treatment , it is continuous used for 72 hours.
Long-term animal studies on the carcinogenic potential of eptifibatide are not made. the Ames test, mouse lymphoma cells (L 5178Y, TK +/-) forward mutation test, the human lymphocyte chromosome aberration assay, or mouse micronucleus test, have shown that eptifibatide is not genotoxic. continuous infusion for a daily dose of the Eptifibatide reaching 72 mg/kg/day (calculated according to body surface area, it is 4 times of the maximum recommended human daily dose), has no effect on fertility and reproductive capacity of male and female rats.
The above information is edited by the Chemicalbook of Tian Ye.

Eptifibatide Preparation Products And Raw materials

Raw materials

Preparation Products


Eptifibatide Suppliers

Global( 161)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Cellmano Biotech Limited
+86-551-65326643
+86-551-65326641 info@cellmano.com CHINA 1044 58
Rixing Chemical CO.,LTD
13237129059
- info@rixingchemi.com CHINA 186 55
Alpha Biopharmaceuticals Co., Ltd
0086-411-39042497
0086-411-39042693 sales@alphabiopharm.com China 921 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22631 55
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 30052 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 23979 58
Hubei Jusheng Technology Co.,Ltd.
86-18871470254
027-59599243 linda@hubeijusheng.com CHINA 28235 58
Beijing Yibai Biotechnology Co., Ltd
0086-182-6772-3597
sales01@yibaibiotech.com CHINA 419 58
Chongqing Chemdad Co., Ltd
+86-13650506873
sales@chemdad.com CHINA 35438 58
Zhuozhou Wenxi import and Export Co., Ltd
+8613111626072
+8613111626072 zzwenxi@126.com CHINA 7497 58

View Lastest Price from Eptifibatide manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2019-08-07 Eptifibatide
148031-34-9
US $3.00 / KG 1KG 99% 100kg career henan chemical co

148031-34-9(Eptifibatide)Related Search:


  • Eptifitide
  • Mpr-Harg-Gly-Asp-Trp-Pro-Cys-NH2,( Disulfide Bridg on Mpr and Cys)
  • EFTIFIBATIDE
  • 3-Mercaptopropionyl-HoMoarg-Gly-Asp-Trp-Pro-Cys-NH2 acetate salt (Disulfide bond)
  • Map-Har-Gly-Asp-Trp-Pro-Cys-NH2(Disulfide bridge, Map1-Cys6)
  • n6-(aminoiminomethyl)-n2-(3-mercapto-1-oxopropyl-l-lysylglycyl-l-a-aspartyl-l-tryptophyl-l-prolyl-l-cysteinamide
  • INTEGRELIN
  • EPTIFIBATIDE ACETATE
  • MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2
  • Mpr-Harg-Gly-Asp-Trp-Pro-Cys-NH2,( Disulfide Bridge:1-7)
  • Eptifibatide
  • Human Eptifibatide
  • 148031-34-9
  • 14803-34-9
  • C35H49N11O9
  • proteins
  • Amino Acid Derivatives
  • Peptide
Copyright 2017 © ChemicalBook. All rights reserved